Topical calcineurin inhibitors

Comprehensive Dermatologic Drug Therapy: Expert Consult - Online and Print

Volumn , Issue , 2012, Pages 535-542

  Lin, Andrew N ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84892580162     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4377-2003-7.00044-3     Document Type: Chapter

References (136)

1. Nghiem P, Pearson G, Langley RG Tacrolimus and pimecrolus: from clever prokaryotes to inhibiting calcinuerin and treating atopic dermatitis. J Am Acad Dermatol 2002, 46:228-241.
2. Pereira U, Boulais N, Lebonvallet N, et al. Mechanisms of the sensory effects of tacrolimus on the skin. Br J Dermatol 2010, 163:70-77.
3. Yan J, Chen SL, Wang L, et al. Meta-analysis of tacrolimus ointment for atopic dermatitis in pediatric patients. Pediatr Dermatol 2008, 25:117-120.
4. Chen SL, Yan J, Wang FX Two topical calcineurin inhibitors for the treatment of atopic dermatitis in pediatric patients: a meta-analysis of randomized clinical trials. J Dermatol Treat 2010, 21(3):144-156.
5. Maged M, Bosseila MA, Mashaly HM, et al. Topical calcineurin inhibitors in atopic dermatitis: a systematic review and meta-analysis. J Dermatol Sci 2009, 54:76-87.
6. Svensson A, Chambers C, Ganemo A, et al. A systematic review of tacrolimus ointment compared with corticosteroids in the treatment of atopic dermatitis. Curr Med Res Opin 2011, 27:1395-1406.
7. Fleischer AB, Boguniewicz M An approach to pruritus in atopic dermatitis: a critical systematic review of the tacrolimus ointment literature. J Drugs Dermatol 2010, 9(5):488-498.
8. Mandelin J, Remitz A, Virtanen H, Reitamo S One-year treatment with 0.1% tacrolimus ointment versus a corticosteroid regimen in adults with moderate to severe atopic dermatitis: a randomized, double-blind comparative trial. Acta Dermatovenereol 2010, 90(2):170-174.
9. Nakagawa H Comparison of the efficacy and safety of tacrolimus ointment with topical corticosteroids in adult patients with atopic dermatitis: review of randomized, double-blind clinical studies conducted in Japan. Clin Drug Invest 2006, 26:235-246.
10. Ingram JR, Martin JA, Finlay AY Impact of topical calcineurin inhibitors on quality of life in patients with atopic dermatitis. Am J Clin Dermatol 2009, 10(4):229-237.
11. Kalavala M, Dohil MA Calcineurin inhibitors in pediatric atopic dermatitis: a review of current evidence. Am J Clin Dermatol 2011, 12(1):15-24.
12. Thaci D, Chambers C, Sidhu M, et al. Twice weekly treatment with tacrolimus 0.03% ointment in children with atopic dermatitis: clinical efficacy and economic impact over 12 months. J Eur Acad Dermatol Venereol 2010, 24(9):1040-1046.
13. Paller AS, Eichenfeld LF, Kirsner RS, et al. Three times weekly tacrolimus ointment reduces relapse in stabilized atopic dermatitis: a new paradigm for use. Pediatrics 2008, 122(6):e1210-e1218.
14. Breneman D, Fleischer ABJ, Abramovits W, et al. Intermittent therapy for flare prevention and long-term disease control in stabilized atopic dermatitis: a randomized comparison of 3 times weekly applications of tacrolimus ointment versus vehicle. J Am Acad Dermatol 2008, 58(6):990-999.
15. Wollenberg A, Reitam S, Girolomoni G, et al. Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment. Allergy 2008, 63(7):742-750.
16. Schmitt J, von Kobyletzki L, Svensson A, Apfelbacher C Efficacy and tolerability of proactive treatment with topical corticosteroids and calcineurin inhibitors for atopic eczema: systemic review and meta-analysis of randomized controlled trials. Br J Dermatol 2011, 164(2):415-428.
17. Abramovits W, Fleischer AB, Jaracz E, et al. Adult patients with moderate atopic dermatitis: tacrolimus ointment versus pimecrolimus cream. J Drugs Dermatol 2008, 7(12):1153-1158.
18. Kirsner RS, Heffernan MP, Antaya R Safety and efficacy of tacrolimus ointment versus pimecrolimus cream in the treatment of patients with atopic dermatitis previously treated with corticosteroids. Acta DermatoVenereol 2010, 90(1):58-64.
19. Yang LP, Curran MP Topical pimecrolimus: a review of its use in the management of pediatric atopic dermatitis. Paediatric Drugs 2009, 11:407-426.
20. Lin AN Innovative use of topical calcineurin inhibitors. Dermatol Clin 2010, 28(3):535-545.
21. Samycia M, Lin AN. Efficacy of topical calcineurin inhibitors in lichen planus. J Cutan Med Surg (in press).
22. Hodgson TA, Sahni N, Kaliakatsou F, et al. Long term efficacy and safety of topical tacrolimus in the management of ulcerative/oral erosive oral lichen planus. Eur J Dermatol 2003, 13(5):466-470.
23. Wallemcq P, Armstrong VW, Brunet M, et al. Opportunities to optimize tacrolimus therapy in solid organ transplanation: report of the European consensus conference. Ther Drug Monit 2009, 31(2):139-152.
24. Ujiie H, Shibaki A, Akiyama M, et al. Successful treatment of nail lichen planus with topical tacrolimus. Acta Dermatovenereol 2010, 90(2):218-219.
25. Lubaki LJ, Ghanem G, Vereecken P, et al. Time-kinetic study of repigmentation in vitiligo patients by tacrolimus or pimecrolimus. Arch Dermatol Res 2010, 302(2):131-137.
26. Lepe V, Moncada B, Castanedo-Cazares JP, et al. A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo. Arch Dermatol 2003, 139(5):581-585.
27. Kawalek AZ, Spencer JM, Phelps RG Combined excimer laser and topical tacrolimus for the treatment of vitiligo: a pilot study. Dermatol Surg 2004, 30(2 Pt 1):130-135.
28. Passeron T, Ostovari N, Zakaria W, et al. Topical tacrolimus and the 308-nm excimer laser: a synergistic combination for the treatment of vitiligo. Arch Dermatol 2004, 140(9):1065-1069.
29. Mehrabi D, Pandya AG A randomized, placebo-controlled, double-blind trial comparing narrowband UV-B plus 0.1% tacrolimus ointment with narrowband UV-B plus placebo in the treatment of generalized vitiligo. Arch Dermatol 2006, 142(7):927-929.
30. Radakovic S, Breier-Maly J, Konschitzky R, et al. Response of vitiligo to once- vs. twice-daily topical tacrolimus: a controlled prospective, randomized, observer-blinded trial. J Eur Acad Dermatovenereol 2009, 23(8):951-953.
31. Lo YH, Cheng GS, Huang CC, et al. Efficacy of topical tacrolimus for the treatment of face and neck vitiligo. J Dermatol 2010, 37(2):125-129.
32. Lebwohl M, Freeman AK, Chapman MS, et al. Tacrolimus is effective for facial and intertriginous psoriasis. J Am Acad Dermatol 2004, 51(15):723-730.
33. Liao YH, Chiu HC, Tseng YS, et al. Comparison of cutaneous tolerance and efficacy of calcitriol 0.3mcg/g ointment and tacrolimus 0.3mg/g ointment in chronic plaque psoriasis involving facial or genital/femoral areas: a double-blind randomized controlled trial. Br J Dermatol 2007, 157(5):1005-1012.
34. Tzung TY, Liu YS, Chang HW Tacrolimus vs clobetasol in treatment of facial cutaneous LE: a randomized double-blind bilateral comparison study. Br J Dermatol 2007, 156(1):191-192.
35. Avgerinou G, Papafragkaki DK, Naiopoulou A, et al. Effectiveness of topical calcineurin inhibitors as monotherapy or in combination with hydroxychloroquine in cutaneous lupus erythematosus. J Eur Acad Dermatol Venereol 2011, (in press) Available on line. doi: 10.1111/j.1468-3083.2011.04161.x.
36. Marzano AV, Trevisan V, Lazzari R, et al. Topical tacrolimus for the treatment of localized, idiopathic, newly diagnosed pyoderma gangrenosum. J Dermatol Treat 2010, 21(3):140-143.
37. Kontos AP, Kerr HA, Fivenson DP, et al. An open-label study of topical tacrolimus ointment 0.1% under occlusion for the treatment of pyoderma gangrenosum. Int J Dermatol 2006, 45(11):1383-1385.
38. Chandrasekhara PK, Jayachandran NV, Thomas J, et al. Successful treatment of pyoderma gangrenosum associated with juvenile idiopathic arthritis with a combination of topical tacrolimus and oral prednisone. Clin Rheumatol 2009, 28(4):489-490.
39. Perez-Nobayna N, Rodriguez-Garcia C, Gonzalez-Hernandez S, et al. Successful response to topical tacrolimus for a granuloma faciale in an elderly patient. Dermatology 2009, 219(4):359-360.
40. Marcoval J, Moreno A, Bordas X, et al. Granuloma faciale: treatment with topical tacrolimus. J Am Acad Dermatol 2006, 55(5 Suppl):S110-S111.
41. Belsito D, Wilson DC, Warshaw R, et al. A prospective randomized clinical trial of 0.1% tacrolimus ointment in a model of chronic allergic contact dermatitis. J Am Acad Dermatol 2006, 55(1):40-46.
42. Saripalli YV, Gadzia JE, Belsito DV Tacrolimus ointment 0.1% in the treatment of nickel-induced allergic contact dermatitis. J Am Acad Dermatol 2003, 49(3):477-482.
43. Pacor ML, Di Lorenzo G, Martinelli N, et al. Tacrolimus ointment in nickel sulphate-induced steroid-resistant allergic contact dermatitis. Allergy Asthma Proc 2006, 27(6):527-531.
44. Bhardwaj SS, Jaimes JP, Liu A, et al. A double-blind randomized placebo-controlled pilot study comparing topical immunomodulating agents and corticosteroids for treatment of experimentally induced nickel contact dermatitis. Dermatitis 2007, 18:26-31.
45. Katsarou A, Armenaka M, Vosynioti V, et al. Tacrolimus ointment 0.1% in the treatment of allergic contact eyelid dermatitis. J Eur Acad Dermatol Venereol 2009, 23(4):382-387.
46. Nakada T, Iijima M, Maibach HI Eyeglass frame allergic contact dermatitis: does tacrolimus prevent recurrences?. Contact Dermatitis 2005, 53(4):219-221.
47. Kroft EB, Groeneveld TJ, Seyger MM, et al. Efficacy of topical tacrolimus in active plaque morphea: randomized, double blind emollient-controlled pilot study. Am J Clin Dermatol 2009, 10(3):181-187.
48. Stefanaki C, Stefanaki K, Kontochristopoulos G, et al. Topical tacrolimus ointment in the treatment of localized scleroderma. An open label clinical and histological study. J Dermatol 2008, 35(11):712-718.
49. Mancuso G, Berdondini RM Localized scleroderma: response to occlusive treatment with tacrolimus ointment. Br J Dermatol 2005, 152(1):180-182.
50. Mancusso G, Berdondini RM Topical tacrolimus in the treatment of localized scleroderma. Eur J Dermatol 2003, 13(6):590.
51. Azad J, Dawn G, Shaffrali, et al. Does solitary morphea profunda progress?. Clin Exper Dermatol 2004, 29:25-27.
52. Hui RL, Lide W, Chan J, et al. Association between exposure to topical tacrolimus or pimecrolimus and cancer. Ann Pharmacother 2009, 43(12):1956-1963.
53. Margolis DJ, Hoffstad O, Bilker W Lack of association between exposure to topical calcineurin inhibitors and skin cancer in adults. Dermatology 2007, 214(4):289-295.
54. Arallano FM, Wentworth CE, Arana A, et al. Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. J Invest Dermatol 2007, 127(4):808-816.
55. Arellano FM, Arana A, Wentworth CE, et al. Lymphoma among patients with atopic dermatitis and/or treated with topical immunosuppressants in the United Kingdom. J Allergy Clin Immunol 2009, 123(5):1111-1116.
56. Tennis, et al. Evaluation of cancer risk related to atopic dermatitis and use of topical calcineurin inhibitors. Br J Dermatol 2011, (in press) Available on line. Doi: 10.1111/j.1365-2133.2011.10363.x'.
57. Berger TG, Duvic M, Van Voorhees AS, et al. The use of topical calcineurin inhibitors in dermatology: safety concerns. Report of the American Academy of Dermatology Association Task Force. J Am Acad Dermatol 2006, 54(5):818-823.
58. Thaci D, Salgo R Malignancy concerns of topical calcineurin inhibitors for atopic dermatitis: facts and controversies. Clin Dermatol 2010, 28(1):52-56.
59. Munzenbuerger PJ, Montejo JM Safety of topical calcineurin inhibitors for the treatment of atopic dermatitis. Pharmacotherapy 2007, 27(7):1020-1028.
60. Remitz A, Reitamo S Long-term safety of tacrolimus ointment in atopic dermatitis. Expert Opin Drug Saf 2009, 8(4):501-506.
61. Schneeweiss S, Doherty M, Zhu S, et al. Topical treatments with pimecrolimus, tacrolimus and medium to high-potentcy corticosteroids, and risk of lymphoma. Dermatology 2009, 219(1):7-21.
62. Lan CC, Yu HS.Huang SM, et al. Topical tacrolimus has limited direct effect on ultraviolet B-irradiated kertinocytes: implications for its photocarcinogenic poteneital. Clin Exper Dermatol 2009, 35(2):173-179.
63. Lerche Topical pimecrolimus and tacrolimus do not accelerate photocarcinogenesis in hairless mice after UVA or simulated solar radiation. Exper Dermatol 2009, 18:246.
64. Krueger GG, Eichenfield L, Goodman JJ, et al. Pharmacokinetics of tacrolimus following topical application of tacrolimus ointment in adult and pediatric patients with moderate to severe atopic dermatitis. J Drugs Dermatol 2007, 6(2):185-193.
65. Reitamo S, Mandelin J, Rubins A, et al. The pharmacokinetics of tacrolimus after first and repeated dosing with 0.03% ointment in infants with atopic dermatitis. Int J Dematol 2009, 48(4):348-355.
66. Undre NA, Moloney FJ, Ahmadi S, et al. Skin and systemic pharmacokinetics of tacrolimus following topical application of tacrolimus ointment in adults with moderate to severe atopic dermatitis. Br J Dermatol 2009, 160(3):665-669.
67. Allen A, Siegfried E, Silverman R, et al. Significant absorption of topical tacrolimus in 3 patients with Netherton syndrome. Arch Dermatol 2001, 137(6):747-750.
68. Shah KN, Yan AC Low but detectable serum levels of tacrolimus seen with the use of very dilute, extemporaneously compounded formulations of tacrolimus ointment in the treatment of patients with Netherton syndrome. Arch Dermatol 2006, 142(10):1362-1363.
69. Saif GB, Al-Khenaizan S Netherton syndrome: successful use of topical tacrolimus and pimecrolimus in four siblings. Int J Dermatol 2007, 46(3):290-294.
70. Oji V, Beljan G, Beier K, et al. Topical pimecrolimus: a novel therapeutic option for Netherton syndrome. Br J Dermatol 2005, 153(5):1067-1068.
71. Stinco G, Piccirillo F, Sallustio M, et al. Facial flush reaction after alcohol ingestion during topical pimecrolimus and tacrolimus treatment. Dermatology 2009, 218(1):71-72.
72. Fujiwara S, Okubo Y, Irisawa R, et al. Rosaceiform dermatitis associated with topical tacrolimus treatment. J Am Acad Dermatol 2010, 62(6):1050-1052.
73. Bakos L, Bakos RM Facial acne during topical tacrolimus therapy for vitiligo. Arch Dermatol 2007, 143(9):1223-1224.
74. Bilenchi R, Poggiali S, De Padova LA, et al. Human papillomavirus reactivation following topical tacrolimus therapy of anogenital lichen sclerosus. Br J Dermatol 2007, 156(2):405-406.
75. Fiorentino DF, Chen RO, Stewart DB, et al. The direct cellular target of topically applied pimecrolimus may not be infiltrating lymphocytes. Br J Dermatol 2011, 164(5):996-1003.
76. Eichenfeld LF, Thaci D, de Prost Y, et al. Clinical management of atopic eczema with pimecrolimus cream in paediatric patients. Dermatology 1997, 215(Suppl 1):3-17.
77. Yang LP, Curran MP Spotlight on topical pimecrolimus in pediatric atopic dermatitis. Am J Clin Dermatol 2010, 11(4):295-298.
78. Kapoor R, Hoffstad O, Bilker W, et al. The frequency and intensity of topical pimecrolimus treatment in children with physician-confirmed mild to moderate atopic dermatitis. Pediatr Dermatol 2009, 26(6):682-687.
79. Zuberbier T, Brautigam M Long-term management of facial atopic eczema with pimecrolimus cream in paediatric patients with mild to moderate disease. J Eur Acad Dermatol Venereol 2008, 22(6):718-721.
80. Murell DF, Calvieri S, Ortonne JP, et al. A randomized controlled trial of pimecrolimus cream in adolescents and adults with head and neck atopic dermatitis and intolerant of, or dependent on, topical corticosteroids. Br J Dermatol 2007, 157(5):954-959.
81. Zurberbier T, Heinzerling L, Bieber T, et al. Steroid-sparing effect of pimecrolimus cream 1% in children with severe atopic dermatitis. Dermatology 2007, 215(4):325-330.
82. Kaurmann R, Bieber T, Helgesen AL, et al. Onset of pruritus relief with pimecrolimus cream 1% in adult patients with atopic dermatitis: a randomized trial. Allergy 2006, 61(3):375-381.
83. Spergel JM, Boguniewicz M, Paller AS, et al. Addition of topical pimecrolimus to once daily mid-potent steroid confers no short-term therapeutic benefit in the treatment of severe atopic dermatitis: a randomized controlled trial. Br J Dermatol 2007, 157(2):378-381.
84. Sigurgeirsson B, Ho V, Ferrandiz C, et al. Effectiveness and safety of a prevention-of-flare-progression strategy with pimecrolimus cream in the management of paediatric atopic dermatitis. J Eur Acad Dermatol Venereol 2008, 22(11):1290-1301.
85. Gollnick H, Kaufmann R, Stough D, et al. Pimecrolimus cream 1% in the long-term management of adult atopic dermatitis: prevention of flare progression. A randomized controlled trial. Br J Dermatol 2008, 158(5):1083-1093.
86. Ruer-Mulard M, Aberer W, Gunstone A, et al. Twice-daily versuss once-daily applications of pimecrolimus cream 1% for the prevention of disease relapse in pediatric patients with atopic dermatitis. Pediatr Dermatol 2009, 26(5):551-558.
87. Dawid M, Veensalu M, Grassberger M, et al. Efficacy and safety of pimecrolimus cream 1% in adult patients with vitiligo: results of a randomized, double-blind, vehicle-controlled study. J Dtsch Dermatol Ges 2006, 4(11):942-946.
88. Eryilmaz A, Seçkin D, Baba M Pimecrolimus: a new choice in the treatment of vitiligo?. J Eur Acad Dermatovenereol 2009, 23(11):1347-1348.
89. Esfandiarpour I, Ekhlasi A, Farajzadeh S, et al. The efficacy of pimecrolimus 1% cream plus narrow-band ultraviolet B in the treatment of vitiligo: a double-blind, placebo-controlled clinical trial. J Dermatolog Treat 2009, 20(1):14-18.
90. Hui-Lan Y, Xiao-Yan H, Jian-Yong F, et al. Combination of 308-nm excimer laser with topical pimecrolimus for the treatment of childhood vitiligo. Pediatr Dermatol 2009, 26(3):354-356.
91. Farajzadeh S, Daraei Z, Esfandiarpour I, et al. The efficacy of pimecrolimus 1% cream combined with microdermabrasion in the treatment of nonsegmental childhood vitiligo: a randomized placebo-controlled study. Pediatr Dermatol 2009, 26(3):286-291.
92. Köse O, Arca E, Kurumlu Z Mometasone cream versus pimecrolimus cream for the treatment of childhood localized vitiligo. J Dermatolog Treat 2010, 21(3):133-139.
93. Queille-Roussel C, Graeber M, Thurston M, et al. SDZ ASM 981 is the first non-steroid that suppresses established nickel contact dermatitis elicited by challenge. Contact Dermatitis 2000, 42:349.
94. Mensing CO, Mensing CH, Mensing H, et al. Treatment with pimecrolimus cream 1% clears irritant dermatitis of the periocular region, face, and neck. Int J Dermatol 2008, 47(9):960-964.
95. Erkek E, Kazkayasi M, Bozdogan O Acute actinic cheilitis-like chemical irritant reaction following accidental contact with etythlene glycol - favorable reponse to topical 1% pimecrolimus cream: a case report. Cutan Ocular Toxicol 2008, 27(2):91-95.
96. DiCostanzo L, Balato N, Zagaria O, et al. Successful management of a delayed and persistent cutaneous reaction to jellyfish with pimecrolimus. J Dermatolog Treat 2008, 20(3):179-180.
97. Warshaw EM, Wohlhuter RJ, Liu A, et al. Results of a randomized double-blind vehicle-controlled efficacy trial or pimecrolimus cream for treatment of moderate to severe facial seborrheic dermatitis. J Am Acad Dermatol 2007, 57(2):257-265.
98. Firooz A, Solhpour A, Gorouhi F, et al. Pimecrolimus cream, 1%, vs hydrocortisone acetate cream, 1%, in the treatment of facial seborrheic dermatitis: a randomized, investigator-blind, clinical trial. Arch Dermatol 2006, 142(8):1066-1067.
99. Cicek D, Kandi B, Bakar S, et al. Pimecrolimus 1% cream, methylprednisolone aceponate 0.1% cream and metronidazole 0.75% gel in the treatment of seborrheic dermatitis: a randomized, clinical study. J Dermatolog Treat 2009, 20(6):344-349.
100. Koc. An open randomized prospective comparative study of topical pimecrolimus 1% cream and topical ketoconazole 1% cream in the treatment of seborrheic dermatitis. J Dermatolog Treat 2009, 20(1):4-9.
101. deMoraes AP, de Arruda EA, Vitoriano MA, et al. An open-label efficacy pilot study with pimecrolimus cream 1% in adults with facial seborrhoeic deramtitis infected with HIV. J Eur Acad Dermatol Venereol 2007, 21(5):596-601.
102. Ozden MG, Tekin NS, Ilter N, et al. Topical pimecrolimus 1% cream for resistant seborrheic dermatitis of the face: an open label study. Am J Clin Dermatol 2010, 11(1):51-54.
103. Kim BS, Kim SH, Kim MB, et al. Treatment of facial seborrheic dermatitis with pimecrolimus cream: an open-label clinical study in Korean patients. J Korean Med Sci 2007, 22(5):868-872.
104. Tatlican S, Eren C, Oktay B, et al. Experience with repetitive use of pimecrolimus: exploring the effective and safe use in the treatment of relapsing seborrheic dermatitis. J Dermatolog Treat 2010, 21(2):83-85.
105. Tatlican S, Eren C, Eskioglu F Insight into pimecrolimus experience in seborrheic dermatitis: close follow-up with exact mean cure and remission times and side-effect profile. J Dermatolog Treat 2009, 20(4):198-202.
106. Cook BA, Warshaw EM Role of topical calcineurin inhibitors in the treatment of seborrheic dermatitis: a review of pathophysiology, safety, and efficacy. Am J Clin Dermatol 2009, 10(2):103-118.
107. Weissenbacher S, Merkl J, Hildebrandt B, et al. Pimecrolimus cream 1% for papulopustular rosacea: a randomized vehicle-controlled double-blind trial. Br J Dermatol 2007, 156:728-732.
108. Karabulut AA, Izol Serel B, Eksioglu HM A randomized, single-blind, placebo-controlled, split-face study with pimecrolimus cream 1% for papulopustular rosacea. J Eur Acad Dermatol Venereol 2008, 22(6):729-734.
109. Koca R, Altinyazar HC, Ankarali H, et al. A comparison of metronidazole 1% cream and pimecrolimus 1% cream in the treatment of patients with papulopustular rosacea: a randomized open-label clinical trial. Clin Exp Dermatol 2009, 35(3):251-256.
110. Lee DH, Li K, Suh DH Pimecrolimus 1% cream for the treatment of steroid-induced rosacea: an 8-week split-face clinical trial. Br J Dermatol 2008, 158(5):1069-1076.
111. Chu CY An open-label pilot study to evaluate the safety and efficacy of topically applied pimecrolimus cream for the treatment of steroid-induced rosacea-like eruption. J Eur Acad Dermatol Venereol 2007, 21:484-490.
112. Barikbin B, Givrad S, Yousefi M, et al. Pimecrolimus 1% cream versus betamethasone 17-valerate 0.1% cream in the treatment of facial discoid lupus erythematosus: a double-blind, randomized pilot study. Clin Exp Dermatol 2009, 34(7):776-780.
113. Tlacuilo-Parra A, Guevara-Gutierrez E, Gutierrez-Murillo F, et al. Pimecrolimus 1% cream for the treatment of discoid lupus erythematosus. Rheumatology 2005, 44(12):1564.
114. Kreuter A, Gambichler T, Breuckmann F, et al. Pimecrolimus 1% cream for cutaneous lupus erythematosus. J Am Acad Dermatol 2004, 51:407.
115. Zabawski E Treatment of cutaneous lupus with Elidel. Dermatol Online J 2002, 8(2):25.
116. Schwarz T, Kreiselmaier I, Bieber T, et al. A randomized double-blind vehicle-controlled study of 1% pimecrolimus cream in adult patients with perioral dermatitis. J Am Acad Dermatol 2008, 59(1):34-40.
117. Oppel T, Pavicic T, Kamann S, et al. Pimecrolimus cream 1% efficacy in perioral dermatitis - results of a randomized, double-blind vehicle-controlled study in 40 patients. J Eur Acad Dermatol Venereol 2007, 21(9):1175-1180.
118. Goldstein AT, Creasey A, Pfau R, et al. A double-blind, randomized controlled trial of clobetasol versus pimecrolimus in patients with vulvar lichen sclerosus. J Am Acad Dermatol 2011, 64(6):e99-104.
119. Zangrilli A, Campione E, Diluvio L, et al. Treatment of disfiguring chronic graft versus host disease in a child with topical pimecrolimus. Pediatr Int 2010, 52(3):e161-e163.
120. Rappersberger K, Komar M, Ebelin ME, et al. Pimecrolimus identifies a common genomic anti-inflammatory profile, is clinically hightly effective in psoriasis and is well tolerated. J Invest Dermatol 2002, 119(4):876-887.
121. Yan AC, Honig PJ, Ming ME, et al. The safety and efficacy of pimecrolimus 1% cream for the treatment of Netherton syndrome: results from an exploratory study. Arch Dermatol 2010, 146(1):57-62.
122. Thaci D, Patzold S, Schwanner S, et al. Comel-Netherton syndrome: a case treated with topical pimecrolimus cream 1%. J Eur Acad Dermatol Venereol 2004, 18(Suppl 2):160-161.
123. Ghorbani AR, Feily A, Khalili A, et al. Lack of efficacy of topical calcineurin inhibitor pimecrolimus 1% on pruritus of severely uremic patients: a randomized double-blind study in 60 patients. Dermatitis 2011, 22:167-168.
124. Pérez-Carmona L, Fleta-Asín B, Moreno-García-Del-Real C, et al. Successful treatment of Darier's disease with topical pimecrolimus. Eur J Dermatol 2011, 21(2):301-302.
125. Iraji F, Asilian A, Siadat AH Pimecrolimus 1% cream in the treatment of cutaneous lesions of pemphigus vulgaris: a double-blind, placebo-controlled clinical trial. J Drugs Dermatol 2010, 9(6):684-686.
126. Correia O, Duarte AF, Quirino P, et al. Cutaneous mastocytosis: two pediatric cases treated with topical pimecrolimus. Dermatol Online J 2010, 16(5):8.
127. Eichenfeld LF, Ho V, Matsunaga J, et al. Blood concentrations, tolerability and efficacy of pimecrolimus cream 1% in Japanese infants and children with atopic dermatitis. J Dermatol 2007, 34(4):231-236.
128. Van Leent EJ, De Vries HJ, Ebelin ME, et al. Blood concentrations of pimecrolimus in adult patients with atopic dermatitis following intermittent administration of pimecrolimus cream for up to one year. J Dermatolog Treat 2007, 18(1):19-22.
129. Lakhanpaul M, Davies T, Allen BR, et al. Low systemic exposure in infants with atopic dermatitis in a one-year pharmacokinetic study with pimecrolimus cream. Exper Dermatol 2006, 15(2):138-141.
130. Werfel T Topical use of pimecrolimus in atopic dermatitis: update on the safety and efficacy. J Dtsch Dermatol Ges 2009, 7(9):739-742.
131. Thaci D, Salgo R The topical calcineurin inhibitor pimecrolimus in atopic dermatitis: a safety update. Acta Dermatovenereol Alpina 2007, 16(2):60-62.
132. Ogunleye T, James WD Ethanol induced flushing with topical pimecrolimus use. Dermatitis 2008, 19(2):E1-E2.
133. Li JC, Xu AE Facial acne during topical pimecrolimus therapy for vitiligo. Clin Exper Dermatol 2009, 34(7):e489-e490.
134. Goksugur. Molluscum contagiosum infection associated with pimecrolimus use in pityriasis alaba. Pediatr Dermatol 2007, 24(5):E63-E65.
135. Fischer G, Bradford J Topical immunosuppressants, genital lichen sclerosus and the risk of squamous cell carcinoma: a case report. J Reproduct Med 2007, 52(4):329-331.
136. Segura S, Romero D, Carrera C, et al. Eczema herpeticum during treatment of atopic dermatitis with 1% pimecrolimus cream. Acta Dermatovenereol 2005, 85(6):524-525.